In Early Trading Today, Lexicon Announces significant and Rapid improvements in their Phase 2 Study of LX4211. After only four weeks of dosing, average percent hemoglobin A1c (HbA1c), a measure of blood glucose levels over time, was significantly reduced by 1.15 in the 150 mg dose group (p=0.036) and by 1.25 in the 300 mg dose group (p=0.017), as compared to 0.49 in the placebo group. The new drug is also aiding meaningful weight loss which is favorable for the extended safety of those suffering from type 2 Diabetes.
Dr. Philip M. Brown stated: "Results from this important first trial of LX4211 in diabetic patients exceeded our expectations.”
Lexicon is currently trading at 2.63, up .66 or 34%. The Biotech company is trading at 2,842,155 well over its average 700,000. BioPharm has been extra volatile as of late since the market as a whole seems to be in limbo. Press releases have speculators jumping at anything at moves. Congratulations to Lexicon for moving step closer to solving a very real problem here in the U.S. and around the Globe.
LX4211 was developed at Lexicon as a potent inhibitor of the sodium glucose cotransporter 2 (SGLT2), a transporter responsible for the majority of glucose reabsorption by the kidneys. Lexicon found that mouse knockouts engineered to lack the SGLT2 gene are healthy and require less insulin to manage a glucose challenge. LX4211 may potentially treat diabetes by improving glycemic control as well as providing other metabolic benefits.
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.